2011 to 2000 DIRECTOR OF MARKETING, DISPOSABLESINFUSION DATA MANAGER 2005 to 2012CARDINAL HEALTH/ALARIS PRODUCTS/CAREFUSION San Diego, CA 2000 to 2011CARDINAL HEALTH/ALARIS PRODUCTS/CAREFUSION
2002 to 2005 PROJECT MANAGERCARDINAL HEALTH/ALARIS PRODUCTS/CAREFUSION
2000 to 2002 CLINICAL CONSULTANTKETTERING MEDICAL CENTER
1998 to 2000 MANAGERKETTERING MEDICAL CENTER Kettering, OH 1988 to 2000KETTERING MEDICAL CENTER
1994 to 1998 MANAGERKETTERING MEDICAL CENTER
1988 to 1994 CRITICAL CARE RN
Education:
SINCLAIR COMMUNITY COLLEGE Dayton Dayton, OH 1988 Associates of Sciences in Nursing
Antitrust & Trade Regulations Antitrust Intellectual Property Antitrust and Competition Law Federal Circuit and IP Appeals Intellectual Prop. Intellectual Property Issues and Appeals Litigation Patent Securities & Corporate Finance Securities Law Trademark and Copyright
ISLN:
909658548
Admitted:
1994
University:
Ripon College, B.A., 1986; University of Wisconsin, Madison, B.S.E.E., 1988
Zacharia S. Cheruvallath - San Diego CA Vasulinga T. Ravikumar - Carlsbad CA Douglas L. Cole - San Diego CA
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C07H 2100
US Classification:
536 231, 536 243, 536 245, 536 2534, 435 6
Abstract:
Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, phosphorodithioate, or other covalent linkages. Also provided are synthetic intermediates useful in such processes.
Reagent Useful For Synthesizing Sulfurized Oligonucleotide Analogs
Zacharia S. Cheruvallath - San Diego CA Vasulinga T. Ravikumar - Carlsbad CA Douglas L. Cole - San Diego CA Daniel C. Capaldi - San Diego CA
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C07C32100
US Classification:
568 22, 536 253, 536 2533
Abstract:
The present invention is directed to a method of synthesizing sulfurized oligonucleotide analogs by reacting an oligonucleotide analog containing a phosphorous(III) linkage with a dithiocarbonic acid diester polysulfide having the formula to produce a sulfurized oligonucleotide analog. The diester polysulfide reagent is useful in solution and solid phase oligonucleotide analog synthesis.
Method Of Synthesizing Phosphorothioate Oligonucleotides
This invention presents novel methods for synthesizing phosphorothioate oligonucleotides, using support-bound phosphoramidites. Novel intermediates useful in the methods are also provided.
Trans Cyclopentanyl Purine Analogs Useful As Immunosuppressants
David R. Borcherding - Loveland OH Ronald E. Esser - Berkeley Heights NJ Douglas L. Cole - San Diego CA
Assignee:
Aventis Pharmaceuticals Inc. - Bridgewater NJ
International Classification:
C07D47316
US Classification:
5142634, 544277
Abstract:
This invention relates to Trans cyclopentanyl purine analogs of the formula (1) wherein the substituent in the 3-position on the cyclopentanyl ring is in the Trans configuration relative to the bicyclic substituent, Y , Y Y , Y are each nitrogen and Y is a CH group, R is a hydrogen, a C alkyl acyl or aryl acyl, Q is NH , halogen or hydrogen, Z is hydrogen, halogen, or NH ; or a pharmaceutically-acceptable salt thereof, and to their use as immunosuppressants.
Compounds For The Synthesis Of Nucleotide Or Oligonucleotide Phosphoramidites
Richard H. Griffey - Vista CA Douglas L. Cole - San Diego CA Vasulinga Ravikumar - Carlsbad CA
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C07H 2100
US Classification:
536 231, 536 2531, 536 2534
Abstract:
This invention presents novel methods for recovery of phosphoramidites from the waste products of oligonucleotide synthesis. The methods include reacting a tribromophenoxydichlorophosphorane with an H-phosphonate in the presence of an amine.
Compounds For The Synthesis Of Nucleotide Or Oligonucleotide Phosphoramidites
Richard H. Griffey - Vista CA Douglas L. Cole - San Diego CA Vasulinga Ravikumar - Carlsbad CA
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C07H 2100
US Classification:
536 231, 536 2534, 536 255, 536 256
Abstract:
This invention presents novel methods for recovery of phophoramidites from the waste products of oligonucleotide synthesis. The methods include reacting a tribromophenoxydichlorophosphorane with an H-phosphonate in the presence of an amine.
Vasulinga T. Ravikumar - Carlsbad CA Muthiah Manoharan - Carlsbad CA Daniel C. Capaldi - San Diego CA Achim Krotz - San Diego CA Douglas L. Cole - San Diego CA Andrei Guzaev - Carlsbad CA
Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, phosphorodithioate, or other covalent linkages. The oligomers have substantially reduced exocyclic adducts deriving from acrylonitrile or related contaminants.
Synthetic processes are provided for the solution phase synthesis of oligonucleotides, especially phosphorothioate oligonucleotides, and intermediate compounds useful in the processes. Intermediates having structure are prepared in accord with preferred embodiments.
Past: Group Communications Officer at NYK Line (North America), Sr. Manager Sales Adminstration... An award-winning “C-level” marketing executive with unparalleled success in all areas of group communications, public relations, new business development... An award-winning “C-level” marketing executive with unparalleled success in all areas of group communications, public relations, new business development and advertising. Analytical, intelligent, and self motivated professional with more than 20 years of experience creating and developing...
Takeda Pharmaceuticals USA president Douglas Cole said, "Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience."
Date: Jan 29, 2013
Category: Health
Source: Google
Takeda Diabetes Drug Succeeding Actos Wins FDA Approval
Millions of people are affected by diabetes and, as aleader in the diabetes arena, Takeda is dedicated to working toadvance patient care and helping to meet the needs of thisgrowing patient population, Douglas Cole, president ofTakedas U.S. subsidiary, said in a statement.
Date: Jan 27, 2013
Category: Health
Source: Google
Takeda seeks to corner market on gout with $800 million acquisition
Douglas Cole, president of Takeda Pharmaceuticals U.S.A. Inc., said the primary goal of the URL acquisition was to gain Colcrys, "so we can be the only company that treats both acute and chronic gout."
This acquisition expands Takedas gout treatment portfolio and leverages our expertise in primary care, said Douglas Cole, president of Takeda Pharmaceuticals U.S.A. We are pleased to have URL Pharmas Colcrys added to our product portfolio.